<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00243048</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000446088</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-D-2325</secondary_id>
    <nct_id>NCT00243048</nct_id>
  </id_info>
  <brief_title>Isoflavones and Radiation Therapy in Treating Patients With Localized Prostate Cancer</brief_title>
  <official_title>Phase II Randomized Study of Soy Isoflavones in Patients With Localized Prostate Cancer Treated With Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Eating a diet high in soy foods may slow the progression of some types of cancer.&#xD;
      Isoflavones are compounds found in soy food that may slow the growth of prostate cancer cells&#xD;
      and prevent further development of prostate cancer. Radiation therapy uses high-energy x-rays&#xD;
      to kill tumor cells. Giving isoflavones together with radiation therapy may be an effective&#xD;
      treatment for prostate cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying the side effects and how well giving&#xD;
      isoflavones together with radiation therapy works in treating patients with localized&#xD;
      prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the effect of soy protein isolate (isoflavones) and radiotherapy on the&#xD;
           modulation of biomarkers in patients with localized prostate cancer.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the effect of this regimen on the quality of life of these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, placebo-controlled study. Patients are randomized to 1 of 2&#xD;
      treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral soy protein isolate (isoflavones) twice daily for 6 months&#xD;
           in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive an oral placebo twice daily for 6 months in the absence of&#xD;
           disease progression or unacceptable toxicity.&#xD;
&#xD;
      In both arms, patients also undergo radiotherapy while receiving isoflavones or placebo.&#xD;
&#xD;
      Quality of life is assessed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 70 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Oxidative DNA damage at 3 and 6 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by questionnaire at 3 and 6 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as measured by number and grade of adverse events weekly during radiation and at 3 and 6 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response as measured by prostate-specific antigen and clinical assessment at 3 and 6 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Isoflavone serum level at 3 and 6 months</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>soy protein isolate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate that is localized to the&#xD;
             prostate gland&#xD;
&#xD;
          -  Must be scheduled to receive curative radiotherapy for prostate cancer&#xD;
&#xD;
          -  Not eligible for a higher priority study at the Karmanos Cancer Institute&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  0-3&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No organ function restrictions&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No prior hormonal therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent micronutrient supplements, herbs, or vitamins except 1 daily&#xD;
             multivitamin&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omer Kucuk, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>October 20, 2005</study_first_submitted>
  <study_first_submitted_qc>October 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2005</study_first_posted>
  <last_update_submitted>April 3, 2013</last_update_submitted>
  <last_update_submitted_qc>April 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage II prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

